VCB-1203

VCB-1203 is a sponsor-code **anti-PD-L1 CAR-T cell therapy** being developed by Vaxcell Bio for solid tumors. Public reports describe it as a chimeric antigen receptor T-cell product directed against **programmed death-ligand 1**, with nonclinical claims of antitumor activity, safety, and stability, and intended use in refractory or recurrent **gastric cancer, colorectal cancer, pancreatic cancer, and ovarian cancer**. Based on currently identifiable public information, VCB-1203 appears to be a preclinical or very early-stage cell therapy program supported by patent and company-announcement coverage rather than clearly registered interventional clinical trial evidence.